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Background: Smoking cessation interventions for hospitalized smokers are effective in promoting smoking
cessation, but only if the tobacco dependence treatment continues after the patient leaves the hospital. Sustaining
tobacco dependence treatment after hospital discharge is a challenge for health care systems. Our previous single-site
randomized controlled trial demonstrated the effectiveness of an intervention that facilitated the delivery
of comprehensive tobacco cessation treatment, including both medication and counseling, after hospital
discharge. We subsequently streamlined the intervention model to increase its potential for dissemination. This
new model is being tested in a larger multi-site trial with broader eligibility criteria in order to enroll a more
representative sample of hospitalized smokers. This paper describes the trial design and contrasts it with the
earlier study.
Methods/Design: A 2-arm, 3-site randomized controlled trial is testing the hypothesis that a multi-component
Sustained Care intervention is more effective than Standard Care in helping hospitalized cigarette smokers stop
smoking after hospital discharge. The trial enrolls adult daily cigarette smokers who are admitted to 1 of 3
participating hospitals in Massachusetts or Pennsylvania. Participants receive the same smoking cessation intervention
in the hospital. They are randomly assigned to receive either Standard Care or Sustained Care after hospital discharge.
Participants in the Sustained Care arm receive a free 3-month supply of FDA-approved smoking cessation medication
and 5 interactive voice response calls that provide tailored motivational messages, medication refills, and access to a
live tobacco treatment counselor. Participants in the Standard Care arm receive a smoking cessation medication
recommendation and information about community resources. Outcomes are assessed at 1, 3, and 6 months after
discharge. The primary outcome is biochemically-validated tobacco abstinence for the past 7 days at 6-month
follow-up. Other outcome measures include self-reported tobacco abstinence measures, use of medication and
counseling after discharge, hospital readmissions, and program cost-effectiveness.
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Discussion: We adapted a proven intervention for hospitalized smokers to enhance its potential for dissemination and
are testing it in a multi-site trial. Study enrollment data suggests that the trial achieved the goal of recruiting a broader
sample of hospitalized smokers.
Trial registration: Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers (Helping HAND2)
NCT01714323. Registered October 22, 2012.
Keywords: Smoking cessation, Hospitalization, Pharmacotherapy, Counseling, Interactive voice response, Randomized
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Cigarette smoking is the leading preventable cause of
death in the United States, responsible for nearly 500,000
deaths annually [1]. Stopping smoking increases life ex-
pectancy at any age [2]. Over half of smokers attempt to
quit each year [3]. Using evidence-based treatment,
consisting of pharmacotherapy and counseling sup-
port, increases the success of a quit attempt, but only
one-third of smokers use any treatment when trying
to quit [3].
Each year nearly four million smokers in the United
States spend at least one night in a hospital [4]. A
hospital admission provides a smoker with a unique
opportunity to quit for several reasons. Hospital policy
requires smokers to abstain temporarily from tobacco
use. If the admission is attributable to a tobacco-related
illness, hospitalization may make the risk of tobacco use
more personally relevant and increase a smoker’s motiv-
ation to quit [5]. Hospital staff can encourage smoking
cessation at this teachable moment and guide the
smoker to resources to sustain smoking cessation after
discharge. Smokers may be given nicotine replacement
therapy (NRT) to relieve nicotine withdrawal symptoms
during the hospital stay. This provides the smoker per-
sonal experience with an effective treatment that he or
she may have avoided due to misinformation about its
risks [6]. Smokers who use NRT in the hospital are more
likely to use it after discharge [7].
Starting a smoking cessation intervention in the hos-
pital increases the odds that a smoker will stop smok-
ing after discharge. Counseling and use of NRT each
improve cessation rates, but these interventions have
long-lasting effects only if continued for more than a
month after hospital discharge [8]. However, many
smokers have no plans to sustain tobacco treatment
after hospital discharge. Health insurers may not
cover the cost of non-prescription NRT that may have
been recommended to smokers at discharge [9,10].
Smokers often return home to a household containing
other smokers or to an environment filled with other
cues to smoke. Consequently, nearly half of all
smokers return to smoking within three days of hos-
pital discharge [11].We previously developed a multi-component interven-
tion to bridge the gap between inpatient and outpatient
cessation services by facilitating smokers’ access to the
two components of effective tobacco dependence treat-
ment, pharmacotherapy and counseling support, after
hospital discharge [12]. To encourage medication use,
patients received a free 30-day supply of their choice of
smoking cessation pharmacotherapy at discharge, with
the option of two free refills. This eliminated patients’
expenditures and avoided the need to visit a pharmacy
to obtain medication. In a variety of settings, reducing
barriers to obtaining free cessation medications has been
shown to increase the use of medications by smokers
who are trying to quit [13-19].
The intervention used interactive voice response (IVR)
technology to sustain contact with smokers after dis-
charge. IVR is a telephone technology in which a com-
puter detects a voice and touch tones, and responds to
callers with a pre-recorded audio script [20]. When ap-
plied in the post-discharge setting, automated calls can
serve multiple functions. IVR calls provide an efficient
method to achieve rapid telephone contact soon after
discharge, when patients are at a high risk for relapse.
IVR calls remind patients of their plan to quit smoking,
provide motivational messages to encourage cessation
efforts and promote medication adherence, and facilitate
medication refills. IVR calls can also triage patients to
live counselors who can provide additional support and
encourage adherence to medications by assessing and
managing side effects. By using a computer as opposed
to a human caller, the IVR system reduces the cost of
contacting smokers and can reach patients at their pre-
ferred calling times by calling outside of normal business
hours. IVR systems have previously been shown to be
efficacious in sustaining contact with smokers after dis-
charge. In a pre-post study, Reid and colleagues used an
IVR system, which increased 6-month continuous quit
rates from 18% to 29% [21].
We tested the effectiveness of our post-discharge to-
bacco treatment model in the Helping Hospital-initiated
Assistance for Nicotine Dependence study (Helping
HAND 1), a randomized controlled trial of 397 smokers
admitted to one large Boston, MA, hospital. Smokers
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pital and planned to quit smoking after discharge were
randomly assigned to the Sustained Care intervention,
which provided free medication and IVR follow-up for
3 months, or to Standard Care. Smokers assigned to
Sustained Care were more likely to use smoking cessa-
tion therapy (both pharmacotherapy and counseling)
after hospital discharge and were more likely to achieve
the primary outcome measure, biochemically-validated
past 7-day tobacco abstinence at 6 month follow-up
(26% vs. 15%; RR 1.71, 95% CI, 1.14-2.56) [22].
The current study, Helping HAND 2 (HH2), builds on
the Helping HAND 1 (HH1) trial in several ways that
aim to test the intervention’s potential when applied to a
more diverse patient population and setting (Table 1).
To determine whether the HH1 study findings apply to
a more diverse population, we broadened study inclusion
criteria to include smokers with alcohol and other sub-
stance abuse. Although they have a high prevalence of
smoking [23], these individuals had been excluded from
the HH1 trial because of concern about medical or psy-
chiatric instability. We also prioritized the recruitment
of smokers with HIV infection, who also have a high
smoking prevalence [24]. Furthermore, we expanded the
program from one to three hospitals located in two
states and included both academic and community
hospitals. Additionally, we streamlined the intervention
in order to facilitate its adoption into actual clinical
practice. To access a live counselor, participants in the
HH1 study used the IVR system to request a separateTable 1 Major study design differences between Helping HAN
Characteristics Helping HAND 1 Helping HAND 2
Enrollment
Study sites MGH MGH, NSMC, UPMC
Enrollment criteria Exclude active alcoholics Include active alcohol
Exclude past year substance
users (except marijuana)
Substance use allowe
admission was for IV d
No suicidal attempt in
past year
No suicidal attempt in
Patients with HIV
infection
Not prioritized Prioritized
Intervention
Counseling after
hospital discharge
Hospital tobacco counselor
by telephone
Quit Coach by teleph
Nicotine Replacement
Therapy after discharge
Refilled and shipped by
hospital study staff
NRT refilled through Q
from Alere warehouse
Follow-up
Follow-up calls 1, 3, and 6 months 1, 3 and 6 months (al
continuously abstinen
follow-up
MGH =Massachusetts General Hospital.
NSMC = North Shore Medical Center.
UPMC = University of Pittsburgh Medical Center.call back from the hospital counselor at a later time. In
contrast, in the HH2 trial, when participants indicate the
desire to speak with a counselor during an IVR call, they
are immediately transferred during that call to a tele-
phone counseling service. That service is identical to a
telephone quitline, a community-based smoking cessation
resource that is available free to every U.S. smoker at www.
smokefree.gov. Finally, to demonstrate the stability of to-
bacco abstinence, we extended follow-up to 12-months to
assess smoking status of participants who reported uninter-
rupted abstinence at 6 months after discharge.
Methods
Study design
HH2 is a multi-center randomized controlled trial test-
ing the hypothesis that the Sustained Care intervention
is more effective than Standard Care in helping hospital-
ized cigarette smokers quit smoking long-term. All
participants receive the same smoking cessation inter-
vention in the hospital and are randomly assigned for
post-discharge care to one of two study arms. All partici-
pants are followed for 6 months; those reporting continu-
ous abstinence at 6 months are followed for an additional
6 months. The primary outcome is biochemically-
validated past 7-day tobacco abstinence rates at 6 month
follow-up. The study is approved by the Partners
Health System Institutional Review Board, the University
of Pittsburgh Institutional Review Board, and is registered
with the National Institutes of Health Clinical Trials
Registry (#NCT01714323).D 1 and Helping HAND 2
Goal of the Change
Increase generalizability
ics Increase generalizability
d unless current
rug overdose
past 3 months
Increase enrollment of vulnerable population
with high prevalence of smoking
one Streamline access to live counselor by
linking IVR call directly to counseling
resource using ‘real world’ counseling resource
uit Coach and shipped Streamline medication refill process using
‘real-world’ design
l) 12 months if
t at 6-month
Determine stability of cessation
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Participants are enrolled from three nonprofit acute care
general hospitals in Massachusetts and Pennsylvania.
Massachusetts General Hospital (MGH) is a 900-bed
urban teaching hospital in Boston, MA, that is affiliated
with Harvard Medical School; it had 49,079 admissions
in 2013. North Shore Medical Center (NSMC) is a 411-
bed suburban community hospital in Salem, MA that
admitted 18,428 patients in 2013. The University of
Pittsburgh Medical Center (UPMC), consisting of
Montefiore and Presbyterian University Hospitals, is a
799-bed urban teaching hospital in Pittsburgh, PA
that had 42,122 admissions in 2013.
Recruitment
Study inclusion and exclusion criteria are listed in
Table 2. A multi-step process identifies eligible patients.
Clinical staff at each site document every patient’s smok-
ing status in the electronic health record at admission.
Each site’s Tobacco Treatment Service (TTS) receives a
daily electronic list of all newly-admitted smokers. A cer-
tified TTS counselor, whose background is in nursing,Table 2 Study inclusion and exclusion criteria
Inclusion criteria
• Admission to a participating hospital
• Received tobacco cessation counseling for > 5 minutes in hospital
• Age ≥18 years
• Current daily smoker (defined as having smoked ≥1 cigarette/day in
the past month when smoking as usual)
• Plan to sustain or initiate a quit attempt immediately after hospital
discharge1
Exclusion criteria
• Non-English speaking
• Unable to provide informed consent due to serious cognitive
impairment or impaired mental status (e.g., current diagnosis of
schizophrenia, psychosis, dementia, or severe mental retardation)
• Life expectancy of <1 year
• Are admitted to the hospital from a nursing home
• Admission diagnosis of intravenous drug use overdose
• Attempted suicide in the past 3 months
• Pregnant or nursing
• Do not agree to take tobacco cessation medication home at
discharge
• No mailing address
• No phone where can be directly reached or unable to communicate
by telephone
• Decline to speak to study staff or have insufficient time before
discharge to be enrolled
• Are not expected to be discharged home or to a rehabilitation facility
1Assessed by asking the smoker to endorse one of 4 responses (‘I will stay
quit’, ‘I will try to quit’, ‘I don’t know if I’m going to quit’, ‘I do not plan to quit’).
Only smokers who endorse the first 2 responses are eligible for study
enrollment.social work, or health education, attempts to see each
newly-admitted smoker at bedside, usually 24-48
hours after hospital admission. Following a protocol,
the counselor assesses nicotine withdrawal symptoms
and recommends that most smokers receive NRT for
withdrawal symptom relief during hospitalization. Be-
cause previous studies have found combination NRT
to be more effective than single NRT products [25],
the usual recommendation is a combination of NRT
products, consisting of the nicotine patch supple-
mented by a short-acting product (nicotine lozenge,
inhaler, or gum) that is used as needed to suppress
nicotine withdrawal symptoms.
The TTS counselor also inquires about patients’ plan
regarding their smoking after hospital discharge. If a pa-
tient clearly is not motivated to quit, contact time with
the TTS counselor is typically less than five minutes.
These patients are not referred for study recruitment.
Patients who plan to stay quit or try to quit after dis-
charge receive a median of 20 minutes of bedside coun-
seling to create a personalized quit plan. The session
includes a specific smoking cessation medication recom-
mendation, tips on how to abstain from smoking after
discharge, and information about counseling services
available after discharge. At the end of the counseling
session, the TTS counselor offers smokers who plan to
quit after discharge and meet inclusion criteria informa-
tion about the study and refers them to research staff for
recruitment. Research staff visit the smoker in the hos-
pital to describe the study, assess eligibility, obtain in-
formed consent, collect baseline data, and assign the
patient to a study arm. Research staff also prioritize the
recruitment of patients with HIV infection on any day
when such a patient is referred to them. The partici-
pant’s primary care physician is notified about the trial
and about any medications prescribed with a note in the
electronic health record or by fax.
Assignment to treatment group
At each study site participants are randomly assigned to
either Standard Care or Sustained Care by research
staff in a 1:1 fashion using permuted blocks of 8.
Randomization is stratified into five groups: four strata
were created by crossing daily cigarette consumption
(<10 versus ≥10 cigarettes per day) with admitting ser-
vice (cardiac vs. non cardiac), and a fifth stratum was
created for HIV-infected patients. A series of sealed
manila envelopes was created for each stratum, with
the randomization ID on the outside of the envelope
and the study arm assignment inside the envelope.
The research assistant informs the participant and
initiates the protocol for the assigned study arm. The
study is not blinded to participants or to research
staff, but enrollment and follow up activities are
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with recruitment.
Interventions
Sustained care
The multi-component Sustained Care intervention facili-
tates access to two components of effective tobacco de-
pendence treatment, pharmacotherapy and counseling
support, following discharge [26]. It uses IVR technology
to provide counseling support and medication man-
agement after discharge and offers participants up to
90 days of free smoking cessation pharmacotherapy,
with a 30-day supply provided in hand at discharge.Greeting
Smoking status ass
Tailored message
counseling recommended 
Positiv
Medication use ass
Positive tailored message 
Side effect assessment
Counseling 
recommended 
Refill Offer
Transfer of
Quit CoacRegistration agent
Counselin
Assess and refill
Closing
Smoking
Yes No
Transfer request-1st time transfer
NRT request P
Using medication
Tr
rep
Figure 1 Sample Interactive Voice Response and Quit Coach design.The intervention closely resembles the Sustained Care
intervention of the HH1 trial, differing primarily in
how counseling is provided to smokers who request it
during an IVR call [12].Interactive voice response (IVR)
The IVR system provides automated telephone calls at 2,
12, 28, 58, and 88 days after discharge (Figure 1). For
each call, the IVR system makes up to 8 attempts to
reach participants for each scheduled call, beginning on
the scheduled call day and proceeding with 2 attempts
per day for 4 days or until the call is completed.essment 
Confidence assessment
e tailored message Tailored message
counseling recommended 
essment
Side effect assessment
Counseling 
recommended 
Positive tailored 
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fer 
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Notify site study staff
Study staff assess and 
refill
Abstinent
High Low
Not using medication
Yes No
Decline transfer
rescription refill request
ansfer request-
eat transfer
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current use of smoking cessation medication, medication
side effects, and offers the option of connection to live
telephone counseling support. The automated call de-
livers motivational messages specifically tailored to the
participant’s progress in his or her quit attempt. For ex-
ample, smokers who failed to use medication after dis-
charge hear, “Using medicine doubles your chance of
quitting smoking for good. We recommend that you talk
with our tobacco counselor about how to get started on
your medicine”.
Any participant can request to speak with a smoking
cessation counselor during any automated IVR call.
Additionally, the IVR system specifically recommends
that participants whose responses meet the pre-specified
criteria speak to a live counselor. Criteria that trigger the
system to recommend a transfer include the following:
(1) participants who have not started their smoking
cessation medication after discharge or prematurely
stopped using pharmacotherapy prior to a 90-day
course; (2) participants who returned to smoking after
discharge but still wish to quit; (3) participants who are
quit but have low confidence in their ability to remain
abstinent; (4) participants who report having medication
side effects; and (5) participants who are due for a medi-
cation refill.
Access to smoking cessation telephone counseling support
An innovation of the HH2 study is the facilitation of
real-time transfer from the automated call to a live tele-
phone counselor in order to maximize treatment con-
tinuity at the time of need. This immediate transfer is
made possible through coordination between the IVR
provider, TelASK Technologies (Ottawa, Canada), and
the telephone counseling provider, Alere Wellbeing Inc.,
(Seattle, WA) (Table 1). Alere offers its standard proto-
col of up to 5 proactive telephone counseling calls over
3 months to support a quit attempt [27]. The goal is to
have a seamless link between IVR monitoring and re-
quest for telephone counseling support. Alere staff also
provide smokers with NRT refills when these are due,
thereby facilitating medication adherence.
Upon transfer from the IVR system to the quitline
provider, the participant speaks to a registration agent
who collects basic information and then routes the caller
to a smoking cessation counselor (“Quit Coach”). The
Quit Coach provides the following: (1) an introduction,
presenting an overview of topics and the purpose of the
call; (2) assessment of the participant’s smoking history,
confidence and motivation to quit; (3) specific insight for
the participant—summarizing the participant’s strengths,
weaknesses, and barriers to quitting; (4) an action plan,
which consists of setting a realistic quit date, brainstorm-
ing strategies to cope with urges, planning to rehearsecoping skills, and addressing medication use, environmen-
tal factors, and social support; and (5) schedule for the
next call, tailored to the participant’s quit date. The Quit
Coach calls the participant for up to 4 additional counsel-
ing sessions. Call 2 is scheduled on or around the quit date
and includes management of withdrawal symptoms,
appropriate use of medications, strategies to maintain
abstinence in high-risk situations, and early relapse
prevention. Calls 3 through 5 focus on relapse preven-
tion and addressing participant concerns and ques-
tions [28]. In addition, once registered with Alere, a
participant can call in to speak with a Quit Coach
directly at any time.
Pharmacotherapy
A free 1-month supply of FDA-approved smoking cessa-
tion pharmacotherapy is delivered to the participant
prior to discharge. Cessation medication options include
NRT (nicotine patches, lozenges, or gum), bupropion, or
varenicline. Either a single medication, or more com-
monly, a combination of medications is prescribed (e.g.,
nicotine patch and lozenge). The participant chooses
the pharmacotherapy, guided by the hospital tobacco
counselor, who considers the participants’ number of
cigarettes smoked daily, time to smoking first cigarette
in the morning, participant preference, past cessation
medication experience, and medical contraindications.
The hospital physician writes the prescription which is
filled by the hospital pharmacy or, at NSMC, a com-
munity pharmacy. All participants receive a handout
with information on proper medication use, side ef-
fects, and instructions on how to obtain the two add-
itional months of free medications through the IVR,
quitline, and study staff. On rare occasions when a partici-
pant is discharged before receiving the prescribed cessa-
tion medication in hand, the research staff ships the
medication using overnight delivery and calls the partici-
pant to ensure receipt of the medication.
When a participant requests a free refill of NRT, the
Quit Coach asks about current medication use, reviews
medication prescribed upon discharge, revisits exclusion
questions, and refills the medication. An automatic de-
livery system from Alere’s warehouse delivers the medi-
cation within 48-72 hours. To refill a prescription-only
cessation medication, a Quit Coach notifies a member of
the research staff, and the study staff assesses medication
use and side effects with the participant. Subsequently
the research staff arranges to have the refill shipped
from the pharmacy through which it was originally filled
(Figure 1).
Standard care
Participants assigned to the Standard Care group receive
the same bedside counseling session in the hospital as
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smokers about post-discharge counseling resources, pro-
vides specific advice to call the state telephone quitline,
makes a specific recommendation to the hospital phys-
ician for post-discharge medication, and completes a
consultation note in the participant’s hospital record. No
additional resources are provided to the participant after
discharge from the hospital.
Assessments
At baseline a survey is administered by research staff im-
mediately after informed consent is obtained. At 1, 3,
and 6 months after hospital discharge, research staff
contact participants by telephone to conduct follow-up
surveys. Participants who report being continuously ab-
stinent from tobacco for 6 months are re-contacted at
12 months.
Prior to each follow-up call, participants are sent a
postcard reminding them that research staff will be con-
tacting them in the near future. The research staff makes
up to 15 call attempts, calling at different times and on
different days, making more attempts during the partici-
pants’ self-reported preferred call time. After an 8th un-
successful call attempt, the research staff calls the
participants’ alternate contacts, people whom the partici-
pants specified would know how to reach them, to verify
the participants’ contact information. Mailed surveys
with a stamped return envelope are sent upon reaching
the 8th and 15th unsuccessful call attempts. Upon reach-
ing a 10th unsuccessful call attempt, the participant re-
ceives a text message requesting a call to the study
hotline. Participants are compensated $20 for complet-
ing each follow-up survey.
At the 6 month follow-up, a participant’s self-report of
past 7-day tobacco abstinence is biochemically con-
firmed. The participant is asked to mail a saliva sample
for assay of cotinine, a nicotine metabolite with a 16-
hour half-life [29]. Because this test is falsely positive for
participants using NRT or electronic cigarettes (e-ciga-
rettes), we request that individuals using either of these
visit the hospital for an expired air carbon monoxide
(CO) test. Participants receive $50 dollars for returning
the cotinine kit or completing a CO test, regardless of
the result obtained. Because smoking status can change
between self-report and the time of saliva collection, we
reassess participants’ use of any form of nicotine in the
7 days prior to the date of saliva collection or CO test.
This includes use of any tobacco products, e-cigarettes,
and nicotine replacement products.
Measures
Participant surveys
The survey instruments cover the following domains
(Table 3).Demographic factors: sex, age, race/ethnicity, educa-
tional attainment, employment status, marital/partner
status, and type of housing are collected by participant
interview and chart review at baseline.
Tobacco use history includes cigarettes per day, use of
other tobacco products, and use of electronic cigarettes
in the month prior to admission, number of years smok-
ing, prior quit attempt (yes/no), presence of a smoker in
the household, and home smoking policy. Prior tobacco
treatment is assessed at baseline by asking about previ-
ous use of NRT, bupropion, varenicline, telephone
counseling support, and in-person counseling support.
Nicotine dependence is assessed by asking time to first
cigarette of the day.
Intention to quit upon discharge is assessed with the
item described in Table 2. Perceived importance of quit-
ting and perceived confidence in ability to quit are
assessed with 5-point Likert-type scales ranging from
“not at all” to “very” at baseline. Confidence is reassessed
at each follow-up.
Alcohol use in the past year is assessed at baseline and
6 months using the three-item Alcohol Use Disorder
Identification Test—Consumption [30]. Other substance
use is assessed at baseline by asking about any use in
the past year of marijuana, cocaine, crack, stimulants,
and opioids. Injection drug use is assessed by asking
about participants’ lifetime use and their use within
the past year.
Anxiety and depression symptoms are assessed at base-
line and at each follow-up using the Patient Health
Quessionaire-4, a 4-item inventory rated on a 4-point
Likert scale ranging from “not at all” to “nearly every
day” [31]. The first two questions measure anxiety symp-
toms and the latter two measure depression symptoms.
Scores range from 0-12, with higher scores indicating
more symptoms.
Quality of life is measured at baseline and 6-month
follow-up using the EQ-5D instrument [32]. It assesses
quality of life on a 5-point Likert scale with answers ran-
ging from “no problems” to “unable” and “not at all” to
“extremely”. The questions range from physical mobility
(problems walking, washing, dressing, pain, and discom-
fort) to psychological (feeling anxious or depressed).
Inpatient experience with tobacco abstinence
At 1-month follow-up, participants rate the difficulty
they had maintaining abstinence in the hospital by an-
swering the question, “How hard was it not to smoke
while you were in the hospital?” (4-point Likert-type
scale, “not at all” to “very”). Participants are asked
whether they used any FDA-approved smoking cessation
medications in the hospital. Cigarette use and electronic
cigarette use while in the hospital are assessed by asking,
“Did you smoke a cigarette (or an electronic cigarette),
Table 3 Helping HAND trial measures and schedule of administration
Baseline Outcomes
Measure 1
Month
3
Month
6
Month
12
Month
Demographic factors
Age, sex, race/ethnicity, educational attainment, employment status, martial/partner status, type of
housing
X
Smoking history
Number of cigarettes per day, use of other tobacco products, use of electronic-cigarette, number of
years smoking, prior quit attempt, smoker in household, home smoking policy
X
Nicotine dependence (time to first cigarette) X
Previous cessation medication use X
Importance in ability to quit X
Confidence in ability to quit/stay quit X X X X
Tobacco abstinence status–self-report
Cigarette smoking status X X X X X1
Non-cigarette tobacco use status X X X X X1
Electronic-cigarette use X X X X X1
Tobacco abstinence status–biochemical validation
Saliva cotinine or expired aired CO X
Quit attempt (>24 hours) X X
Hospital admission or emergency room visit X X X
Quality of life (EQ-5D) X X
Anxiety and depression symptoms (PHQ-4) X X X X
Alcohol use (AUDIT-C) X X
Other non-tobacco substance use X
Satisfaction with IVR X X
Satisfaction with Quit Coach X X
Smoking during index hospital stay X
Smoking cessation medication used after discharge X X X
Smoking cessation counseling used after discharge X X X
Other smoking cessation programs/resources used X X X
Items in bold italics were only in Helping HAND 2.
All other measures were used in both Helping HAND 1 and 2.
1Asked only of participants who self reported continuous abstinence at 6 month follow-up.
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pants who report using either product are asked, “Did
you smoke inside the hospital building, outside, or
both?”
Hospital record review
We obtain health insurance, hospital length of stay, pri-
mary and secondary hospital discharge diagnoses, hos-
pital service, and participants’ disposition after discharge
(home or rehabilitation facility) from hospital records.
Chart review at baseline is done to obtain height, weight,
and history of co-morbid medical diagnoses; these in-
clude hypertension, diabetes, dyslipidemia, myocardial
infarction or coronary heart disease, stroke, cancer
(other than skin), and emphysema or chronic bronchitis.Outcome measures
Tobacco abstinence
The primary smoking outcome is a biochemically-
validated 7-day point prevalence abstinence from all
tobacco products at 6 months after discharge. This is
determined by responses to these questions: “In the
past 7 days have you smoked a cigarette, even a puff?”
and “In the past 7 days, have you used any tobacco
products other than cigarettes such as cigars, pipes,
snus, or chew?” Participants are considered to be
smokers for the primary outcome if they are lost to
follow-up or report tobacco abstinence but do not
provide a biochemical sample that meets criteria for
abstinence (saliva cotinine ≤10 ng/ml or expired air
CO ≤9 ppm).
Reid et al. BMC Public Health  (2015) 15:109 Page 9 of 12Secondary outcome measures of tobacco abstinence
status include the following: (1) self-reported 7-day point
prevalence tobacco abstinence at 1, 3, and 6 months; (2)
self-reported sustained 7-day abstinence from cigarettes
and other tobacco products at 1, 3, and 6 months; (3),
self-reported continuous abstinence from cigarettes and
other tobacco products at 1, 3, 6, and 12 months (‘Since
you left the hospital, have you smoked a cigarette, even
a puff? Have you used any other tobacco products such
as cigars, pipes, snus, or chew?)’; (4) duration of tobacco
abstinence after discharge (How soon after you left the
hospital, did you smoke your first cigarette, even a
puff?); and (5) proportion of participants who make a
24-hour quit attempt after discharge (‘Since you left the
hospital have you not smoked for 24 hours because you
were trying to quit?’).
Whether to classify e-cigarette users as tobacco abstin-
ent or not is under discussion by tobacco researchers.
No clear criteria have yet been adopted. For this study,
we consider e-cigarette use to be comparable to long-
term NRT use. Individuals who report abstinence to all
conventional tobacco products but are using e-cigarettes
and meet criteria for biochemical validation of abstin-
ence by expired air CO are considered to be tobacco ab-
stinent. A sensitivity analysis will be done to determine
how tobacco abstinence rates change when e-cigarettes
only users are classified as tobacco users.
Smoking cessation treatment use and adherence
We hypothesize that the intervention is mediated by
increasing participants’ use of evidence-based pharma-
cotherapy and counseling after discharge. Participants
report on the extent of any use of either modality at
each outcome assessment. Smoking cessation counsel-
ing is defined as telephone or in-person counseling
from any source including a physician. Pharmacotherapy
includes use of NRT (nicotine patch, gum, lozenge,
inhaler, or nasal spray), bupropion, or varenicline. For
medications used, we assess dose, starting date of use,
frequency and duration of use, reason for termination,
and whether the patient changed their dosage due to
side effects.
The principal measure of treatment use is the use of
any pharmacotherapy or counseling after discharge; we
will also calculate the proportion of participants who use
pharmacotherapy and counseling separately. Outcome
measures for pharmacotherapy include any use and dur-
ation of use. Outcome measures for counseling include
any use and number of contacts.
Health care utilization
We will calculate the rate of all-cause re-hospitalizations,
re-hospitalization for coronary heart disease, emergency
room visits, and all-cause deaths over 6 months after theindex hospitalization. Measures include (1) number of
hospital readmissions, (2) length of stay in hospital, (3)
number of emergency room visits, and (4) total number of
hospitalizations and emergency room visits. An electronic
health record tracking system automatically notifies
research staff when a study participant has an emer-
gency room visit or hospitalization at facilities in Part-
ners Healthcare System, the integrated health care
delivery system to which MGH and NSMC belong. At
the end of the study, data on these events will be ob-
tained from Partners billing data. At UPMC, informa-
tion about hospital readmissions to UPMC-affiliated
hospitals is obtained from chart review of participants’
electronic health records.
Information about hospitalizations and emergency
room visits outside UPMC and Partner’s Healthcare
System are obtained from participant surveys, by asking
the questions “Since you were discharged from [hospital
name] on [date] have you gone to the emergency room
or stayed overnight at any hospital? This includes re-
habilitation or skilled nursing facilities”. We request hos-
pital name, type of visit (either ED, admission, inpatient
rehab,) length of stay, and the hospitalization date. This
is supplemented by requesting medical records of admis-
sions to hospitals outside Partners HealthCare System
and UPMC-affiliates.
Program satisfaction
Participants in the Sustained Care arm are asked about
their satisfaction with the telephone counseling by the
Quit Coaches and the automated IVR calls. Participants
who ever spoke to a Quit Coach are asked: (1) “How
helpful was the Quit Coach?” (“not at all” to “very”); (2)
“If a friend or family member who smokes and wanted
to stop were hospitalized, would you recommend that
they speak with a Quit Coach to help them stop smok-
ing?” (“strongly recommend” to “strongly not recom-
mend”); and (3) an open-ended question, “What, if
anything, was helpful or not helpful about the Quit
Coach program?” Those who received at least one IVR
call are asked parallel questions regarding the auto-
mated telephone system, using the same scales. Add-
itionally we ask, “How helpful was it to have the
automated telephone calls refill your stop smoking
medication for you?” (“not at all” to “very”).
Quality assurance
Multiple actions are taken to ensure the consistency of
TTS services, recruitment, and enrollment across all
three sites. These included creating standardized proto-
cols across sites for counseling, referring, and enrolling
patients. All counselors and recruiters were trained to-
gether prior to recruitment, specifically focusing on
inclusion and exclusion criteria. Regular meetings of
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sure that the same standardized protocol is followed
for referrals. Follow-up assessments were centralized
at one study site.
Data analysis
A total sample of 1350 was planned to detect a differ-
ence of 4.8% (12.8% vs. 8.0%) in the primary outcome
measure, validated 7-day tobacco abstinence at 6-month
follow-up, with 80% power and a 2-tailed type I error
rate of .05. Analysis of study data will use an intention-
to-treat approach. In the primary analysis, subjects lost
to follow-up due to all circumstances will be coded as
smokers for smoking status outcomes. A sensitivity ana-
lysis will be conducted based on different assumptions
on missing data [33]. Multiple imputation techniques
will also be used to take into account uncertainty due to
missing data.
Primary outcome
The primary smoking outcome is biochemically-validated
7-day point prevalence abstinence from all tobacco prod-
ucts at 6 month follow-up. For the analysis, Cochran-
Mantel-Haenzel tests will first be used to determine
whether intervention effects are consistent across the 3
study sites. Logistic regression analyses will be used to
compare the effect of study arm on the primary outcome
measure, adjusting for study site.
Secondary outcomes
For all outcomes measured at 1, 3, and 6 months, cross-
sectional analyses will be used to compare between study
groups. Secondarily, a longitudinal analysis using Gener-
alized Estimating Equations (GEE) techniques will be
conducted to assess the overall impact of Sustained Care
by including data from all follow-up times. Similar to
the primary outcome, regression models will be used to
compare treatment group adjusting for site and any im-
portant confounders; these will be logistic regression for
dichotomized outcomes (e.g. self-reported abstinence,
any counseling/medication use), and Poisson regression
for the number of event outcomes (e.g. number of
counseling contacts, number of emergency room visits,
number of hospital readmissions). Survival analysis
techniques will be used to analyze the duration-related
outcome variables (self-reported duration of continuous
abstinence and duration of post-discharge medication
use). Kaplan-Meier curves will be used to estimate the
median duration of tobacco abstinence and medication
use. Cox proportional hazard models will examine
intervention effects adjusting for potential confounding
factors.
Cost-effectiveness will be assessed using cost per quit
as the main outcome in order to compare our resultswith other published studies [22,34,35]. The incremental
costs per quit are estimated as follows: (Total costs of
Sustained Care – Total costs for Standard Care)/(Total
successful quits at six months for Sustained Care –
Total successful quits at six months for Standard Care)
where successful quits are defined according to our pri-
mary outcome of 7-day point prevalence abstinence. The
major costs tracked in the study are as follows: (1) initial
counselor assessment pre-discharge, which includes
counselor chart review, counseling, and medication rec-
ommendations; (2) Quit Coach medication assessment
and cessation support post-discharge; (3) IVR service;
and (4) medication costs, including dispensing and
delivery. For both study arms, we will track the portion
of counseling and medication costs paid for by partici-
pants out of pocket and/or by insurance.
Trial status
A total of 1,359 participants were enrolled in the study
between December 2012 and July 2014. The follow-up
of these participants is in progress. Enrollment data from
the HH2 study can be compared to enrollment data
from the HH1 study to assess whether the HH2 study
met its goal of enrolling a higher proportion of hospital-
ized smokers by broadening the eligibility criteria to per-
mit enrollment of smokers with comorbid alcohol or
other substance abuse. In the HH2 study, 1416 (72%) of
the 1959 smokers who were fully screened met eligibility
criteria and 1359 (69%) were enrolled. By comparison, in
the HH1 study, only 432 (48%) of the 904 smokers who
were fully screened met eligibility criteria and only 397
(44%) enrolled. In the HH2 study only 23 (1%) of 1959
patients were excluded for alcohol or other substance
abuse, compared to 254 patients (28%) of 904 patients
excluded for these reasons in the HH1 study. The HH2
study sample also included a higher proportion of
smokers with HIV infection (4.5% [n = 61] vs. 1% [n = 4]
in the HH1 study). Thus, relaxing the restriction on en-
rolling smokers with non-tobacco substance abuse in the
HH2 study produced a sample that was more represen-
tative of all hospitalized smokers than had been re-
cruited into the HH1 study.
Discussion
The Helping HAND 2 trial tests whether a coordinated
system to sustain smoking cessation treatment initiated
during a hospitalization increases the proportion of hos-
pitalized smokers who are tobacco abstinent 6 months
after discharge. The program aims to achieve this by re-
moving barriers to continued use of smoking cessation
medication and counseling. It resembles the intervention
that was effective in the single-site HH1 trial [12] but
extends this earlier work. It tests the intervention’s ef-
fectiveness in three hospitals in two states, and the
Reid et al. BMC Public Health  (2015) 15:109 Page 11 of 12intervention provides a new real-time direct transfer
from the automated call to a live smoking cessation
counselor when smokers request additional assistance.
HH2 also tests the intervention in a more medically and
socially diverse sample that includes smokers with other
substance abuse or HIV infection, vulnerable popula-
tions whose smoking prevalence exceed that of the gen-
eral population. The study enrollment data demonstrate
that the HH2 study succeeded in its goal of enrolling a
larger proportion of smokers admitted to the study hos-
pitals and including smokers in more vulnerable popula-
tions. Analysis of outcome data, which is still being
collected, will determine whether the intervention will
retain its effectiveness. If effective, this model could be
adopted by U.S. hospitals to help reduce population
smoking rates, thereby decreasing tobacco-related mor-
tality, morbidity, and health care costs.
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